0001144204-15-066696.txt : 20151118 0001144204-15-066696.hdr.sgml : 20151118 20151118160843 ACCESSION NUMBER: 0001144204-15-066696 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20151116 FILED AS OF DATE: 20151118 DATE AS OF CHANGE: 20151118 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: KALOBIOS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001293310 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770557236 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 442 LITTLEFIELD AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650.243.3100 MAIL ADDRESS: STREET 1: 442 LITTLEFIELD AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Shkreli Martin CENTRAL INDEX KEY: 0001525354 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35798 FILM NUMBER: 151240846 MAIL ADDRESS: STREET 1: 330 MADISON AVENUE, 6TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 4 1 v425127_4.xml OWNERSHIP DOCUMENT X0306 4 2015-11-16 0 0001293310 KALOBIOS PHARMACEUTICALS INC KBIO 0001525354 Shkreli Martin C/O TURING PHARMACEUTICALS LLC 1177 AVENUE OF THE AMERICAS, 39TH FLOOR NEW YORK NY 10036 0 0 1 0 Common Stock 2015-11-16 4 P 0 500169 0.61 A 914254 D Common Stock 2015-11-16 4 P 0 97269 1.43 A 1011523 D Common Stock 2015-11-17 4 P 0 606677 1.93 A 1618200 D Common Stock 2015-11-17 4 P 0 7000 2.43 A 1625200 D The price reported in Column 4 is a weighted average price. Martin Shkreli purchased 500,169 shares in multiple transactions at prices ranging from $0.3 to $.79, inclusive. The reporting person undertakes to provide to Kalobios Pharmaceuticals, Inc., any security holder of Kalobios Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. The securities reported herein are owned directly by Martin Shkreli, who is a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934. There is no voting or ownership agreement amongst the group members and the other members of the group do not have a pecuniary interest in the shares reported herein. Correspondingly, Mr. Shkreli does not have a pecuniary interest in the shares owned by the other members of the group. The price reported in Column 4 is a weighted average price. Martin Shkreli purchased 606,677 shares in multiple transactions at prices ranging from $1.38 to $2.37, inclusive. The reporting person undertakes to provide to Kalobios Pharmaceuticals, Inc., any security holder of Kalobios Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4. The price reported in Column 4 is a weighted average price. Martin Shkreli purchased 7,000 shares in multiple transactions at prices ranging from $2.38 to $2.45, inclusive. The reporting person undertakes to provide to Kalobios Pharmaceuticals, Inc., any security holder of Kalobios Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4. s/ Martin Shkreli 2015-11-18